Literature DB >> 32770711

Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid efficiently treated with omalizumab.

Pedro Miguel Garrido1, Maria Inês Alexandre2, Ana Rita Travassos1, Paulo Filipe1,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32770711     DOI： 10.1111/dth.14160

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN： 1396-0296            Impact factor:   2.851


× No keyword cloud information.
  2 in total

1.  Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.

Authors:  Marina Alexandre; Gérôme Bohelay; Thomas Gille; Christelle Le Roux-Villet; Isaac Soued; Florence Morin; Frédéric Caux; Sabine Grootenboer-Mignot; Catherine Prost-Squarcioni
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

Review 2.  Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid.

Authors:  Tong Zhou; Bin Peng; Songmei Geng
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.